Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belotecan - Chong Kun Dang Pharmaceutical

Drug Profile

Belotecan - Chong Kun Dang Pharmaceutical

Alternative Names: Belotecan hydrochloride; Camtobell; CKD 602; EQ-917; S-CKD602

Latest Information Update: 10 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Chonnam National University Hospital; OnKor Pharmaceuticals
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • No development reported Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 10 Jul 2019 No development reported - Phase-II for Ovarian cancer (Recurrent, Second-line therapy or greater) in South Korea (IV) (NDR batch #16)
  • 13 Aug 2015 Phase-IIb development for Ovarian cancer (Recurrent, Second-line therapy or greater) is ongoing in South Korea (NCT01630018)
  • 13 Aug 2015 No recent reports on development identified - Phase-I for Solid tumours in South Korea (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top